The mission of the NRG Oncology Statistics and Data Management Center (SDMC) is to provide all necessary expertise and personnel for the design, conduct and analysis of clinical trials and associated research for NRG Oncology, a member group of the NCI National Clinical Trials Network (NCTN) program. The Statistics Core of the SDMC provides statistical methodology expertise for the conduct of cancer clinical trials and associated research. The Statistics Core is an integral component central to the SDMC and to NRG Oncology as a whole. Statisticians represent the most closely collaborating group within the SDMC with NRG Oncology investigators across the disease sites that the group addresses. In the first cycle (2014-2019) of the NCTN, the NRG Oncology SDMC was successfully formed from existent centers with specific areas of expertise, both in the disease sites and the attendant trial methodology. The SDMC has retained this expertise, but also broadened individuals? roles so that statisticians may engage in new disease sites, trial methodology, and analytic methods. This unification and expansion has strengthened the statistics group. During the first cycle, the statistics group enjoyed a highly productive period, supporting the initiation of 32 new trials and obtaining final approval on an additional 14 trials now in development, while continuing to maintain accrual and/or follow-up to primary and secondary endpoint reporting on over 80 additional trials that were active at the inception of NRG Oncology. With respect to contributions to the total NCTN effort, the accruing NRG Oncology trials during 2014-2017 represent 34% of all accruing NCTN trials. Publications from the group in the first cycle number over 300, including 39 statistics and clinical trials methodology articles by SDMC statisticians. In the second cycle of the NCTN, the Statistics Core will continue to carry out its critical trial conduct functions, beginning with trial design appropriate for the question, using innovative modern methods to develop efficient and maximally informative trials. Approaches such as integrated trial developmental phases and incorporation of modern biomarker-based information will be sought. Analysis plans for primary, secondary, and exploratory aims will reflect state-of-the-art statistical methodology, with novel methods developed as needed. The Statistics Core, working with other components of the SDMC, will provide continuous trial conduct oversight through all stages from concept and protocol development, trial monitoring, initial reporting, and publication. The statisticians will work closely with SDMC data management and information technology personnel to assure secure high-quality data collection, maintenance, and curation for additional discovery and data sharing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180822-08
Application #
10165653
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2014-04-18
Project End
2025-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
8
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hensley, Martee L; Enserro, Danielle; Hatcher, Helen et al. (2018) Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol :JCO1800454
Olawaiye, Alexander B; Java, James J; Krivak, Thomas C et al. (2018) Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 151:18-23
Shi, Wenyin; Scannell Bryan, Molly; Gilbert, Mark R et al. (2018) Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys 100:38-44
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Chinnaiyan, Prakash; Won, Minhee; Wen, Patrick Y et al. (2018) A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol 20:666-673
Boxerman, Jerrold L; Zhang, Zheng; Safriel, Yair et al. (2018) Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro Oncol 20:1400-1410
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2018) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol 41:396-401
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280
Lukka, Himanshu R; Pugh, Stephanie L; Bruner, Deborah W et al. (2018) Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys 102:287-295
Younge, Kelly C; Marsh, Robin B; Owen, Dawn et al. (2018) Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. Int J Radiat Oncol Biol Phys 100:1067-1074

Showing the most recent 10 out of 331 publications